Fitch Even Webinar: January 27, 2021
Please join Fitch Even for a free webinar, “Means Plus Function Claim Construction in Patent Prosecution and Litigation,” on January 27, 2021, at 9:00 a.m. PST / 10:00 a.m. MST / 11:00 a.m. CST / 12 noon EST.
Means plus function claim construction is being applied by courts and the USPTO when the term “means” is not explicitly used. When does this happen, and what is the impact? Understanding the law of means plus function claim construction, as well as its application in litigation and patent prosecution, can provide answers.
During this webinar, we will discuss these topics and more:
- How to identify means plus function claim terms
- How to construe means plus function claim terms
- How to avoid a means plus function claim construction in patent prosecution
- How to use means plus function claim terms in patent prosecution
- Indefiniteness and means plus function claim terms
- Differences between the Doctrine of Equivalents and means plus function equivalents
Our speaker will be Fitch Even partner Jon A. Birmingham. For over 20 years, Jon has represented clients ranging from Fortune 100 companies to startups in intellectual property litigation, opinion matters, and complex patent prosecution matters.
CLE credit has been approved for California, Illinois, and Nebraska. Other states may also award CLE credit upon attendee request. There is no fee to attend, but please note registration is required. To reserve your place, please REGISTER HERE.
IP Alert | Congress Passes New Copyright Legislation in Spending BillJanuary 20, 2021
Last month, Congress passed the Copyright Alternative in Small-Claims Enforcement Act of 2019 (the "CASE Act") as part of the COVID-19 relief bill. Read more
IP Alert | Federal Circuit Finds Apportionment of Damages Was Built Into Royalty Rate from Prior License Between PartiesJanuary 19, 2021
On November 19, in Vectura Limited v. GlaxoSmithKline, the Federal Circuit affirmed a reasonable royalty award relating to infringement of a single patent, using a royalty rate from a prior license agreement involving more than 400 patents without requiring any apportionment. Read more